NICE Single Technology Appraisal Guidance No 240 – Panitumumab
in combination with chemotherapy for the treatment of metastatic
should note that:
1. Recommendations of NICE Single Technology
Appraisals (STAs) have no status in NHSScotland.
2. NHS boards should adhere to the Scottish
Medicines Consortium (SMC) advice.
SMC published a Statement of Advice (769/12) on
this medication for this indication in February 2012. This stated
panitumumab (Vectibix®)is not recommended for
use within NHS Scotland for the treatment of patients with
wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in
combination with FOLFOX; in second-line in combination with
FOLFIRI for patients who have received first-line
fluoropyrimidine-based chemotherapy (excluding irinotecan).
The holder of the marketing authorisation has
not made a submission to SMC regarding this product in this
indication. As a result we cannot recommend its use within
Access the advice of SMC:
3. There is no material difference between the
recommendations of the NICE STA and SMC.
Published Date: 14 December 2011